Business Person of the Month March 2019: Peter Keeling, following Diaceutics listing on London Stock Exchange

Belfast-based diagnostic testing company listed on London Stock Exchange’s international market for smaller growing companies, AIM

Diaceutics is a data analytics and implementation services company servicing the global pharmaceuticals industry. CEO Peter Keeling founded the company in 2005 to collate large amounts of laboratory, patient, claims and payor data which it then uses to deliver diagnostic testing strategies to its clients. The company has amassed data from 2,500 laboratories, including 3.5 million longitudinal patient records, insurance claims data for 50 million patients and 58 million testing event data points from 35 countries.

Due to Diaceutics recent listing on the London Stock Exchange’s international market for smaller growing companies, AIM, and other business successes, including expanding into Asia, Peter Keeling has been selected as our Business Person of the Month for March 2019.

Listing on the London Stock Exchange – DXRX

Speaking about listing, Keeling said,

We are very pleased with the level of interest generated from new institutional investors in support of our admission to trading on AIM. The move to AIM and the additional funding will allow us to continue our growth trajectory by developing our product and services offering which is focused on better testing and better treatment in the global pharmaceutical industry.

He continued, “The name Diaceutics reflects our activities at the intersection between diagnostics and pharmaceuticals, as does the ticker we chose, DXRX which uses DX, the industry short hand for a diagnostic and RX, the one for a prescription drug.We would like to thank our new and existing investors for their support, and the whole Diaceutics team for coming with us on this exciting journey.”

The company raised £17 million through the conditional placing of 22,368,427 new Ordinary Shares at a placing price of 76p which meant a £52.9 million market capitalisation on Admission at the placing price.

Diaceutics is the fourth Northern Irish company listed in London.

A history in diagnostics

With a 10-year career in GlaxoSmithKline as Commercial Director, Indonesia before becoming CEO of his first company, Diagnology, in 1995, Keeling has a long history in the pharmaceuticals industry and Diaceutics itself has been going from strength to strength. The company recently announced an expansion into Asia with a new Singapore hub.

Keeling was a finalist in the 2018 EY Entrepreneur of the Year Awards in the International category and Diaceutics is included in the Ireland INC US 250 Index, an Index of Irish companies operating and investing in the US which recently launched at the New York Stock Exchange on Ireland Day.